alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

109TH CONGRESS 

1ST SESSION H. R. 1845

To suspend temporarily the duty on Bromoxynil Octanoate Tech. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 26, 2005

Mr. GRAVES introduced the following bill; which was referred to the 

Committee on Ways and Means 

A BILL

To suspend temporarily the duty on Bromoxynil Octanoate 

Tech.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. BROMOXYNIL OCTANOATE TECH. 

4 (a) IN GENERAL.—Subchapter II of chapter 99 of 

5 the Harmonized Tariff Schedule of the United States is 

6 amended by inserting in numerical sequence the following 

7 new heading:

‘‘ 9902.06.16 2,6-dibromo-4-cyanophenyl 

octanoate (CAS No. 1689–

99–2) (provided for in subheading 2926.90.23) ............ Free No change No change On or before 

12/31/2008 ’’. 
2

•HR 1845 IH 

1 (b) EFFECTIVE DATE.—The amendment made by 

2 subsection (a) applies to goods entered, or withdrawn from 

3 warehouse for consumption, on or after the 15th day after 

4 the date of enactment of this Act.

Æ
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-2000
<PERIOD-START>                             APR-01-1999
<PERIOD-END>                               DEC-31-1999
<EXCHANGE-RATE>                                  1,000
<CASH>                                           1,930
<SECURITIES>                                         0
<RECEIVABLES>                                    2,116
<ALLOWANCES>                                         0
<INVENTORY>                                      5,984
<CURRENT-ASSETS>                                10,837
<PP&E>                                           5,436
<DEPRECIATION>                                   2,683
<TOTAL-ASSETS>                                  14,722
<CURRENT-LIABILITIES>                            1,281
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        13,070
<OTHER-SE>                                         370
<TOTAL-LIABILITY-AND-EQUITY>                    14,722
<SALES>                                         10,013
<TOTAL-REVENUES>                                     0
<CGS>                                            6,669
<TOTAL-COSTS>                                    4,546
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (1,178)
<INCOME-TAX>                                        93
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (1,271)
<EPS-BASIC>                                      (.13)
<EPS-DILUTED>                                    (.13)


</TABLE>
**Exhibit 31.2**

**CERTIFICATION**

I, Anahita Villafane,certify that:

1.             Ihave reviewed this quarterly report on Form 10-QSB of Aspyra, Inc.;

2.             Basedon my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statementsmade, in light of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report;

3.             Basedon my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the small business issuer asof, and for, the periods presented in this report;

4.             Thesmall business issuer’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer andhave:

(a)           Designedsuch disclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the small business issuer, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

(b)           Evaluatedthe effectiveness of the small business issuer’s disclosure controls andprocedures and presented in this report our conclusions about the effectivenessof the disclosure controls and procedures, as of the end of the period coveredby this report based on such evaluation; and

(c)           Disclosedin this report any change in the small business issuer’s internal control overfinancial reporting that occurred during the small business issuer’s mostrecent fiscal quarter (the small business issuer’s fourth fiscal quarter in thecase of an annual report) that has materially affected, or is reasonably likelyto materially affect, the small business issuer’s internal control overfinancial reporting; and

5.             Thesmall business issuer’s other certifying officer and I have disclosed, based onour most recent evaluation of internal control over financial reporting, to thesmall business issuer’s auditors and the audit committee of small businessissuer’s board of directors (or persons performing the equivalent functions):

(a)           Allsignificant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely to adverselyaffect the small business issuer’s ability to record, process, summarize andreport financial information; and

(b)           Anyfraud, whether or not material, that involves management or other employees whohave a significant role in the small business issuer’s internal control overfinancial reporting.
| Date: August 14, 2006 |   | /s/ Anahita Villafane   |
|-----------------------|--------|-------------------------|
|                  |   | Anahita Villafane       |
|                  |   | Chief Financial Officer |

 

----
UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF INDIANA 

HAMMOND DIVISION 

CONNECTICUT GENERAL LIFE 

INSURANCE COMPANY, et al., 

 Plaintiffs, 

 v. 

NORTHWEST REGIONAL SURGERY 

CENTER, LLC, et al., 

 Defendants. 

)

)

)

)

)

)

)

)

)

) 

Case No. 2:15-CV-253-JD 

ORDER

Plaintiffs’ original complaint alleged that various surgery centers named as Defendants 

engaged in fraudulent “dual pricing” and “fee forgiving” schemes, whereby the surgery centers 

charged their patients little or nothing for out-of-network medical services while charging 

exorbitant rates to the patients’ health insurance plans administered through Cigna [DE 1]. After 

the Defendants filed a motion to dismiss for failure to state a claim [DE 35], the Plaintiffs 

responded by filing an amended complaint [DE 37] which no longer alleges claims under the 

Racketeer Influenced and Corrupt Organizations Act, but adds claims for intentional interference 

with prospective business and civil conspiracy. 

Because the Plaintiffs have filed an amended complaint, the original complaint, which 

was the subject of the Defendants’ motion to dismiss, is of no further effect. Duda v. Bd. of 

Educ. of Franklin Park Pub. Sch. Dist. No. 84, 133 F.3d 1054, 1057 (7th Cir. 1998) (“Once an 

amended pleading is filed, it supersedes the prior pleading.”) (citing Wellness CommunityNational v. Wellness House, 70 F.3d 46, 49 (7th Cir. 1995)); Barnett v. Daley, 32 F.3d 1196, 

1198 (7th Cir. 1994); Buck v. New York Cent. R.R., 275 F.2d 292, 293 (7th Cir. 1960). “The prior 

USDC IN/ND case 2:15-cv-00253-JD-PRC document 38 filed 10/06/15 page 1 of 2
2 

pleading is in effect withdrawn as to all matters not restated in the amended pleading, and 

becomes functus officio.” Duda, 133 F.3d at 1057 (citation and footnote omitted). Because the 

Plaintiffs’ amended complaint is the only complaint before the Court, the original complaint [DE 

1] is a nullity. Therefore, the motion to dismiss the original complaint [DE 35] is DENIED AS 

MOOT. 

 SO ORDERED. 

 ENTERED: October 6, 2015 

 

 /s/ JON E. DEGUILIO 

 Judge 

 United States District Court 

USDC IN/ND case 2:15-cv-00253-JD-PRC document 38 filed 10/06/15 page 2 of 2
UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF INDIANA 

FORT WAYNE DIVISION 

 

UNITED STATES OF AMERICA ) 

 ) 

 v. ) CASE NO.: 1:15-CR-55-TLS-1 

 ) 

MELISSA K. MARTINEZ ) 

 

ORDER ACCEPTING FINDINGS AND RECOMMENDATION 

 This matter is before the Court on the Findings and Recommendation of the United States 

Magistrate Judge [ECF No. 38], filed on February 19, 2016. The Defendant has waived objection 

to the Findings and Recommendation, and the Court, being duly advised, adopts the Findings 

and Recommendation [ECF No. 38] in its entirety and accepts the recommended disposition. 

Subject to this Court’s consideration of the Plea Agreement pursuant to Federal Rule of Criminal 

Procedure 11(c), the plea of guilty to the offense charged in Count Three (3) of the Indictment is 

hereby accepted, and the Defendant is adjudged guilty of such offense. 

 The notice of sentencing and pre-sentence scheduling deadlines will be issued by separate 

order.

SO ORDERED on March 8, 2016. 

 s/ Theresa L. Springmann 

 THERESA L. SPRINGMANN 

 UNITED STATES DISTRICT COURT
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          96,110
<SECURITIES>                                         0
<RECEIVABLES>                                  284,804
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      20,670,452
<DEPRECIATION>                               2,622,502
<TOTAL-ASSETS>                              19,582,079
<CURRENT-LIABILITIES>                                0
<BONDS>                                     12,955,910
<PREFERRED-MANDATORY>                            3,582
<PREFERRED>                                          0
<COMMON>                                       400,000
<OTHER-SE>                                   2,912,535
<TOTAL-LIABILITY-AND-EQUITY>                19,582,079
<SALES>                                      1,715,973
<TOTAL-REVENUES>                             1,797,201
<CGS>                                                0
<TOTAL-COSTS>                                  743,240
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             565,880
<INCOME-PRETAX>                                488,081
<INCOME-TAX>                                   171,060
<INCOME-CONTINUING>                            317,021
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   317,021
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
```
[Federal Register Volume 60, Number 88 (Monday, May 8, 1995)]
[Notices]
[Page 22566]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-11255]

-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Yale University, et al.; Notice of Consolidated Decision on 
Application for Duty-Free Entry of Scientific Instrument

    This is a decision consolidated pursuant to Section 6(c) of the 
Educational, Scientific, and Cultural Materials Importation Act of 1966 
(Pub. L. 89-651, 80 Stat. 897; 15 CFR 301). Related records can be 
viewed between 8:30 AM and 5:00 PM in Room 4211, U.S. Department of 
Commerce, 14th and Constitution Avenue, N.W., Washington, D.C.
    Docket Number: 94-150. Applicant: Yale University, New Haven, CT 
06520. Instrument: Stopped Flow Adaptor for Optical Spectrometer, Model 
RX.1000. Manufacturer: Applied Biophysics Inc., United Kingdom. 
Intended Use: See notice at 60 FR 3394, January 17, 1995.
    Docket Number: 94-151. Applicant: National Institute of Standards 
and Technology, Gaithersburg, MD 20899. Instrument: Multicollector 
System for Mass Spectrometer. Manufacturer: Finnigan MAT, Germany. 
Intended Use: See notice at 60 FR 3394, January 17, 1995.
    Comments: None received. Decision: Approved. No instrument of 
equivalent scientific value to the foreign instruments, for the 
purposes for which the instruments are intended to be used, is being 
manufactured in the United States. Reasons: These are compatible 
accessories for existing instruments for the use of the applicants. The 
National Institutes of Health advises in its memoranda dated March 22, 
1995 that the accessories are pertinent to the intended uses and that 
it knows of no comparable domestic accessories.
    We know of no domestic accessories which can be readily adapted to 
the existing instruments.

Frank W. Creel,
Director, Statutory Import Programs Staff.
[FR Doc. 95-11255 Filed 5-5-95; 8:45 am]
BILLING CODE 3510-DS-F
```
FEDERAL DEPOSIT INSURANCE CORPORATION 

550 17th Street NW, Washington, DC 20429 OFFICE OF THE CHAIRMAN 

February 18, 2021 

Dear Sir/Madam: 

The Federal Deposit Insurance Corporation (FDIC) is pleased to submit its 2020 Annual Report (also referred to as the 

Performance and Accountability Report), which includes the audited financial statements of the Deposit Insurance 

Fund and the Federal Savings and Loan Insurance Corporation (FSLIC) Resolution Fund. This report is produced in 

accordance with: 

♦ Section 17(a) of the Federal Deposit Insurance (FDI) Act, 

♦ the Chief Financial Oficers Act of 1990 (Public Law 101-576), 

♦ the Government Performance and Results Act (GPRA) of 1993 (as amended) and the GPRA Modernization 

Act of 2010, 

♦ Section 5 of the Inspector General Act of 1978, as amended, 

♦ the Reports Consolidation Act of 2000, and 

♦ the Fraud Reduction and Data Analytics Act of 2015. 

In accordance with the Reports Consolidation Act of 2000, the FDIC assessed the reliability of the performance data 

contained in this report. We found no material inadequacies and the data are considered to be complete and reliable. 

Based on internal management evaluations, and in conjunction with the results of independent financial statement 

audits, we can provide reasonable assurance that the objectives of Section 2 (internal controls) and Section 4 

(financial management systems) of the Federal Managers’ Financial Integrity Act of 1982 have been achieved, and 

that the FDIC has no material weaknesses. However, the U.S. Government Accountability Ofice did identify internal 

control over the contractor payment review process as a significant deficiency. The FDIC has eforts underway to 

address this deficiency. We are committed to maintaining efective internal controls corporate-wide in 2021. 

Sincerely, 

Jelena McWilliams 

Chairman 

The President of the United States 

The President of the United States Senate 

The Speaker of the United States House of Representatives 

2
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000713492
<NAME> CHAD THERAPEUTICS, INC.
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          MAR-31-2000
<PERIOD-START>                             APR-01-1999
<PERIOD-END>                               JUN-30-1999
<EXCHANGE-RATE>                                  1,000
<CASH>                                           1,039
<SECURITIES>                                         0
<RECEIVABLES>                                    2,145
<ALLOWANCES>                                         0
<INVENTORY>                                      6,938
<CURRENT-ASSETS>                                11,597
<PP&E>                                           5,388
<DEPRECIATION>                                   2,285
<TOTAL-ASSETS>                                  15,906
<CURRENT-LIABILITIES>                            1,361
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        13,058
<OTHER-SE>                                       1,487
<TOTAL-LIABILITY-AND-EQUITY>                    15,906
<SALES>                                          3,638
<TOTAL-REVENUES>                                     0
<CGS>                                            2,317
<TOTAL-COSTS>                                    1,574
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  (254)
<INCOME-TAX>                                     (100)
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (154)
<EPS-BASIC>                                      (.02)
<EPS-DILUTED>                                    (.02)


</TABLE>
EXHIBIT 32.2 PHARMOS CORPORATION
SECTION 1350 CERTIFICATION In connection
with the quarterly report of PHARMOS CORPORATION, a Nevada corporation (the
Company), on Form 10-Q for the quarter ended June 30, 2007, as filed with the
Securities and Exchange Commission (the Report), I, S. COLIN NEILL, Chief
Financial Officer of the Company, hereby certify as of the date hereof, solely
for purposes of Title 18, Chapter 63, Section 1350 of the United States Code,
that to the best of my knowledge: (1) the Report
fully complies with the requirements of Section 13(a) or 15(d), as applicable,
of the Securities Exchange Act of 1934, and (2) the
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company at the dates
and for the periods indicated. This
Certification has not been, and shall not be deemed, filed with the
Securities and Exchange Commission. Date: August
8, 2007 By:
/s/ S. COLIN
  NEILL A signed original of this
written statement required by Section 906, or other document authenticating,
acknowledging or otherwise adopting the signature that appears in typed form
within the electronic version of this written statement required by Section
906, has been provided to Pharmos Corporation and will be retained by Pharmos
Corporation and furnished to the Securities and Exchange Commission or its
staff upon request.
EX-31 Rule 13a-14(d)/15d-14(d) Certification.


  I, John Isbrandtsen, certify that:

  1. I have reviewed this report on Form 10-K and all reports on Form 10-D
     required to be filed in respect of the period covered by this report on
     Form 10-K of Sequoia Mortgage Trust 2007-4 (the "Exchange Act periodic
     reports");

  2. Based on my knowledge, the Exchange Act periodic reports, taken as a
     whole, do not contain any untrue statement of a material fact or omit
     to state a material fact necessary to make the statements made, in
     light of the circumstances under which such statements were made, not
     misleading with respect to the period covered by this report;

  3. Based on my knowledge, all of the distribution, servicing and other
     information required to be provided under Form 10-D for the period
     covered by this report is included in the Exchange Act periodic reports;

  4. Based on my knowledge and the servicer compliance statements required
     in this report under Item 1123 of Regulation AB, and except as
     disclosed in the Exchange Act periodic reports, the servicers have
     fulfilled their obligations under the servicing agreements in all
     material respects; and

  5. All of the reports on assessment of compliance with servicing criteria
     for asset-backed securities and their related attestation reports on
     assessment of compliance with servicing criteria for asset-backed
     securities required to be included in this report in accordance with
     Item 1122 of Regulation AB and Exchange Act Rules 13a-18 and 15d-18
     have been included as an exhibit to this report, except as otherwise
     disclosed in this report.  Any material instances of noncompliance
     described in such reports have been disclosed in this report on Form
     10-K.

    In giving the certifications above, I have reasonably relied on
    information provided to me by the following unaffiliated parties:
    Cenlar, FSB as Sub-Servicer for Morgan Stanley Credit Corporation, GMAC
    Mortgage, LLC f/k/a GMAC Mortgage Corporation as Servicer, GreenPoint
    Mortgage Funding, Inc. as Servicer, Morgan Stanley Credit Corporation
    as Servicer, PHH Mortgage Corporation as Servicer and Wells Fargo Bank,
    N.A. as Master Servicer and Securities Administrator.

    Dated:   March 28, 2008


    /s/ John Isbrandtsen
    Signature

    Vice President
    (senior officer in charge of securitization of the depositor)
Ekundayo Ayo ERHABOR, petitioner, v. UNITED STATES.

No. 12-10450.

Supreme Court of the United States

June 24, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.